Avicanna Announces Repayment of Debentures
August 30, 2024 07:30 ET
|
Avicanna Inc.
TORONTO, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on...
Avicanna Announces Closing of Non-Brokered Private Placement
August 28, 2024 18:15 ET
|
Avicanna Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES...
Avicanna Announces United States Patent and Trademark Office Issuance of Patent on Topical Technology
August 27, 2024 07:30 ET
|
Avicanna Inc.
USPTO issues Patent No. US 20230025693A1 (“Patent”) that covers Avicanna’s deep penetrating topicalcannabinoid composition and methods for treating musculoskeletal inflammation and pain ...
Avicanna Subsidiary Completes Export of Aureus Branded CBG into Denmark
August 15, 2024 07:30 ET
|
Avicanna Inc.
TORONTO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and...
Avicanna Reports Q2 2024
August 14, 2024 17:45 ET
|
Avicanna Inc.
Q2 2024 revenue of $6.1 million an increase of 85% over Q2 2023Completion of two real world evidence trials on Epidermolysis Bullosa and Musculoskeletal Pain TORONTO, Aug. 14, 2024 (GLOBE NEWSWIRE)...
Avicanna Announces Changes of Auditors
August 02, 2024 17:30 ET
|
Avicanna Inc.
TORONTO, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and...
Avicanna Subsidiary Completes Export of Aureus Branded CBG into Singapore
July 11, 2024 07:30 ET
|
Avicanna Inc.
This marks the first export into Asia, the 18th international market for Aureus branded products and 21st market for all Avicanna products TORONTO, July 11, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc....
Avicanna Announces Results of Annual General Meeting & Provides Corporate Update
July 10, 2024 17:30 ET
|
Avicanna Inc.
TORONTO, July 10, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing,...
Avicanna General Meeting
June 19, 2024 17:30 ET
|
Avicanna Inc.
TORONTO, June 19, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and...
Avicanna Announces USPTO Issuance of Patent SEDDS Technology
June 19, 2024 07:30 ET
|
Avicanna Inc.
TORONTO, June 19, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and...